Nectar Lifesciences Discloses Pledge Release by SBICAP Trustee
Filing Summary
Nectar Lifesciences Ltd has disclosed the release of a pledge on its promoters’ holdings by SBICAP Trustee Company Limited. This action follows the repayment of a loan by Nectar Lifesciences. The disclosure was made in compliance with Regulation 7(3) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The release involved equity shares totaling 9,94,68,000, which constituted 44.35% of the company’s shareholding. The transaction was completed on October 30, 2025, and reported on November 3, 2025. This development is part of Nectar Lifesciences’ ongoing financial management activities.
Nectar Lifesciences Ltd has announced the release of a pledge on its promoters’ holdings by SBICAP Trustee Company Limited. This release follows the repayment of a loan by the company. The disclosure was made in accordance with Regulation 7(3) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The company has already made the necessary disclosures under Regulation 7(2) of the same regulations.
The transaction involved the release of equity shares totaling 9,94,68,000, which represented 44.35% of the company’s shareholding. The nominal value of these equity shares is Rs. 1 per share. The release of the pledge was executed on October 30, 2025, and the company reported this transaction to the stock exchanges on November 3, 2025. The disclosure was addressed to both the National Stock Exchange of India Limited and BSE Limited, under the respective symbols NECLIFE and scrip code 532649.
The role of SBICAP Trustee Company Limited in this transaction was as the Security Trustee for the lenders of Nectar Lifesciences. SBICAP Trustee Company Limited is responsible for holding the security created in its favor for the benefit of the debenture holders or lenders, as required under the transaction documents. The company does not engage in lending or borrowing activities but acts as a trustee to enforce security as per the instructions of the lenders or debenture holders in case of default.
The release of the pledge is part of Nectar Lifesciences’ financial management activities, ensuring compliance with regulatory requirements. The company has taken steps to inform the relevant stock exchanges and maintain transparency with its investors. This action reflects the company’s adherence to the SEBI regulations concerning insider trading and the management of pledged securities.
The timeline for this transaction began with the release of the pledge on October 30, 2025, followed by the formal disclosure to the stock exchanges on November 3, 2025. The involved parties include Nectar Lifesciences Ltd, its promoters, and SBICAP Trustee Company Limited, acting as the Security Trustee.
Nectar Lifesciences Ltd is engaged in the business of manufacturing and marketing pharmaceutical products. The company focuses on maintaining compliance with regulatory standards and managing its financial obligations effectively. Nectar Lifesciences continues to prioritize transparency and adherence to industry regulations in its operations.